Dr Matt Brown
The Royal Marsden Hospital
Matt Brown is a consultant in pain medicine at the Royal Marsden Hospital. He trained at King’s College London, winning the War Memorial and Wolfson Foundation Scholarships and graduating with distinction.
His clinical training in pain medicine was conducted at The Royal National Orthopaedic Hospital and the National Hospital for Neurology and Neurosurgery. Matt fulfilled his long-term interest in clinical research by gaining a National Institute for Health Research’s Academic Clinical Fellowship. This enabled him to conduct novel, award-winning research into pain at both Imperial College and King’s College, London. Subsequently Matt completed a Doctorate in Medicine at the Institute of Cancer Research (becoming the first anaesthetist in the Institute’s history to do so and winning the Chairman’s Prize at graduation).
Matt has published and lectured widely on the subject of pain in cancer. His research interests include pain in cancer survivors, persistent post-surgical pain, chemotherapy induced peripheral neuropathy (CIPN) and the use of high-intensity focused ultrasound (HIFU) to reduce pain from bone metastases.
Pain in Cancer – New Horizons
As the oncological landscape shifts in response to the improved diagnosis and treatment of malignancy, so the causes and types of pain encountered in cancer patients change. Pain is the most feared symptom of patients with advanced cancer and remains a major area of unmet clinical need. Poorly controlled pain results in markedly reduced quality of life and commonly impacts on treatment compliance and overall clinical outcomes. This seminar will provide an overview of current hot-topics in the field of cancer pain including; chemotherapy induced peripheral neuropathy, pain in cancer survivors and the challenges posed by the ‘opioid crisis’.
EVEN MORE SEMINARS
Emlyn Samuel Cancer Research UK
Rob Duncombe The Christie NHS Foundation Trust
Medicine Optimisation in Oncology. How to achieve best value.
Camilo Colaco ImmunoBiology
Professor A. Graham Pockley multimmune GmbH / Nottingham Trent University
A new era of cancer therapeutics?